Table 2.
amplitude (pA)a | deactivation τW (ms)b | |||||||
---|---|---|---|---|---|---|---|---|
control | (S)-EU1180–55 | foldc | N | control | (S)-EU1180–55 | foldc | N | |
GluN1/GluN2A | 768 ± 141 | 1604 ± 297 | 2.1d | 11 | 80 ± 9.7 | 250 ± 24 | 3.1d | 9 |
GluN1/GluN2B | 454 ± 172 | 1290 ± 436 | 2.8d | 7 | 569 ± 45 | 934 ± 47 | 1.6d | 10 |
GluN1/GluN2C | 152 ± 42 | 879 ± 213 | 5.8d | 7 | 513 ± 25 | 716 ± 40 | 1.4d | 16 |
GluN1/GluN2D | 204 ± 51 | 856 ± 215 | 4.2d | 7 | 5510 ± 329 | 6500 ± 357 | 1.2d | 12 |
amplitude (pA)a | deactivation τW (ms)b | |||||||
control | (R)-EU1180–55 | foldc | N | control | (R)-EU1180–55 | foldc | N | |
GluN1/GluN2A | 1020 ± 241 | 1560 ± 364 | 1.5d | 12 | 55 ± 4.5 | 89 ± 6.3 | 1.6d | 8 |
GluN1/GluN2B | 452 ± 143 | 561 ± 179 | 1.2d | 8 | 628 ± 39 | 822 ± 73 | 1.3d | 15 |
GluN1/GluN2C | 158 ± 34 | 811 ± 145 | 5.1d | 7 | 576 ± 28 | 827 ± 42 | 1.4d | 10 |
GluN1/GluN2D | 291 ± 102 | 1120 ± 264 | 3.8d | 6 | 6830 ± 279 | 8010 ± 318 | 1.2d | 13 |
amplitude (pA)a | deactivation τW (ms)b | |||||||
control | (S)-EU1180–154 | foldc | N | control | (S)-EU1180–154 | foldc | N | |
GluN1/GluN2A | 754 ± 196 | 1080 ± 337 | 1.4d | 7 | 79 ± 9.2 | 148 ± 22 | 2.0d | 8 |
GluN1/GluN2B | 600 ± 301 | 1040 ± 418 | 1.7d | 8 | 670 ± 31 | 1001 ± 71 | 1.5d | 10 |
GluN1/GluN2C | 206 ± 58 | 589 ± 170 | 2.9d | 6 | 433 ± 30 | 609 ± 65 | 1.4d | 6 |
GluN1/GluN2D | 201 ± 34 | 580 ± 101 | 2.9d | 7 | 5540 ± 156 | 6660 ± 395 | 1.2d | 9 |
amplitude (pA)a | deactivation τW (ms)b | |||||||
control | (R)-EU1180–154 | foldc | N | control | (R)-EU1180–154 | foldc | N | |
GluN1/GluN2A | 841 ± 146 | 1130 ± 219 | 1.3d | 10 | 56 ± 5.5 | 66 ± 5.9 | 1.3 | 15 |
GluN1/GluN2B | 422 ± 221 | 442 ± 228 | 1.0 | 6 | 616 ± 36 | 720 ± 44 | 1.2d | 12 |
GluN1/GluN2C | 185 ± 48 | 296 ± 77 | 1.6d | 13 | 411 ± 14 | 522 ± 23 | 1.3d | 8 |
GluN1/GluN2D | 227 ± 25 | 313 ± 38 | 1.4d | 15 | 5980 ± 384 | 6360 ± 192 | 1.1 | 7 |
Steady-state current response to 100 μM glutamate plus vehicle and the response amplitude following a direct switch to glutamate plus 15 μM (S)- or (R)-EU1180–55 or 5 μM (S)- or (R)-EU1180–154 were measured using whole cell current recordings from transfected HEK cells. Data shown are mean ± SEM; 30 μM glycine was present in all solutions and recordings were made at −70 mV.
Agonist-evoked currents were recorded in response to rapid application of 100 μM glutamate plus 30 μM glycine for 1.5 s. (S)- or (R)-EU1180–55 (15 μM) or (S)- or (R)-EU1180–154 (5 μM) was added to the glycine-containing wash, and the glutamate/glycine-containing solution and recordings were repeated in the same cell. Recordings were made at −70 mV.
Fold is the ratio of parameter in drug to control.
p < 0.05 by paired t test of amplitude and weighted tau (τW). Power to detect an effect size of 1.5 was 0.8–0.99 for steady-state amplitude and for weighted tau.